Sugammadex
- Generic Name
- Sugammadex
- Brand Names
- Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal
- Drug Type
- Small Molecule
- Chemical Formula
- C72H112O48S8
- CAS Number
- 343306-71-8
- Unique Ingredient Identifier
- 361LPM2T56
- Background
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intuba...
- Indication
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
- Associated Conditions
- Neuromuscular blockade caused by vecuronium bromide
- Associated Therapies
- -
Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 115
- Registration Number
- NCT00474253
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 182
- Registration Number
- NCT00473694
Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 84
- Registration Number
- NCT00451100
Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 198
- Registration Number
- NCT00451217
Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00420680
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00379613
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 224
- Registration Number
- NCT00298831
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath